News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

SAM Medical Products’ Junctional Tourniquet Receives 510K Approval to Control Axilla Hemorrhage

WILSONVILLE, Ore., July 30, 2013 /PRNewswire-iReach/ — SAM Medical Products is pleased to announce it has received 510(k) regulatory clearance from the FDA to add an additional indication of use to the SAM Junctional Tourniquet (SJT).

The new 510K indication allows the SJT to be used to control difficult bleeds in the axilla area. The device now has three purposes – controlling inguinal hemorrhage, controlling axilla hemorrhage and pelvic fracture stabilization. The additional indication of use propels the SJT to the […]

July 30, 2013 |

Sedia Biosciences Corporation Raises $500,000 Equity Investment

Source: Sedia Biosciences Corp
Dated: Jul. 17, 2013

Strategic China partner to aid in access to new international markets for the company’s epidemiological and diagnostic products.

PORTLAND, Ore. — Sedia Biosciences Corporation (Sedia) of Portland, Oregon, USA, a developer and manufacturer of low cost, innovative medical diagnostic tests and surveillance assays to detect and monitor global pandemic diseases today announced that it has completed a Subscription Agreement with Sichuan Jireh Technology Ltd. (the Investor), Sichuan, People’s Republic of China (PRC) for an investment of […]

July 25, 2013 |

AdvaMed Praises House Legislation Exempting

AdvaMed Praises House Legislation Exempting
FDA User Fees from Sequestration

WASHINGTON, D.C. –Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), issued the following statement today following the introduction in the U.S. House of Representatives of bipartisan legislation that would exempt FDA user fees from cuts under sequestration:

“AdvaMed would like to thank Reps. Leonard Lance (R-NJ), Anna Eshoo (D-CA), Doris Matsui (D-CA), Mike Rogers (R-MI) and the other co-sponsors of this legislation, which will allow FDA to have […]

July 24, 2013 |

Lifecom Inc. announces series A financing

Lifecom, Inc., a market leader in clinical decision support solutions, today announced that it has completed a Series A Financing in excess of $1,000,000. Portland area angel investors led the financing round. The company will use the funding to accelerate investments in sales and marketing, product development and engineering.

Lifecom’s CEO and Founder Dr. Steve Datena noted, “Making a difference can sound like such a cliché, but that’s what this is really all about. It’s a privilege to work with such […]

June 27, 2013 |

Statement On U.S. Supreme Court Review Of Isolated DNA Patents

Washington, D.C. (June 13, 2013) Jim Greenwood, President and CEO of the Biotechnology Industry Organization (BIO), today issued the following statement on  the U.S. Supreme Court’s decision regarding Myriad Genetics’ patent claims on isolated DNA molecules:

 “The Supreme Court today summarily ruled that so-called cDNA remains eligible for patenting.  cDNA is the commercially most important form of DNA used in biotechnology.  Today’s decision offers urgently-needed certainty for research-driven companies that rely on cDNA patents for investment in innovation.

“In other respects, however, […]

June 19, 2013 |

SAM Medical Products is pleased to announce the appointment of Will Fox as VP of Marketing and Business Development

SAM Medical Products is pleased to announce the appointment of Will Fox as VP of Marketing and Business Development.   Will has been recruited to help expand our marketing and business development activities in conjunction with SAM Medical’s long term growth plan.
Will has over 20 years experience in sales and marketing in the medical device and surgical implant industries as well as 7 years of military experience as a Naval Officer.

Upon graduation from the University of North Carolina, Will entered the […]

Oregon Bio Nabs $67,000 grant for job creation and workforce development

Oregon Bio’s ‘just-in-time’ training model implements targeted and technical skill expertise from more than 20 professional industry instructors

(Portland, Ore.) — Oregon Bioscience Association (, is the recipient of a unique grant from Worksystems Inc., that will help fund a Portland-area effort to train 260 local incumbent employees who qualify in the H1-B visa targeted employment classifications.

“This $67,000 grant will create a new niche for training employees to update their job skills and prepare them for rapid advancement and recruitment […]

May 25, 2013 |

Sedia Biosciences announces global launch of new research assay to detect recent HIV-1 infections

The Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay, a powerful new tool in the global fight against HIV, measures the maturation of the immune response to identify recent HIV infections among those already identified as positive.

PRLog (Press Release) – May 20, 2013 – PORTLAND, Ore. — Sedia Biosciences Corporation of Portland Oregon, U.S.A., announced today the global launch of a new assay, the Sedia™ HIV-1 Limiting Antigen Avidity Enzyme Immunoassay (“Sedia™ HIV-1 LAg-Avidity EIA”) to epidemiologists, researchers and public health […]

May 21, 2013 |

TriStar Wellness Solutions acquires HemCon Medical Technologies

Developer of Bleeding and Wound Management Technologies for Surgical, Health Care, Consumer and Military Markets to Operate as Wholly Owned Subsidiary of TriStar Wellness Solutions

WESTPORT, Conn.–(BUSINESS WIRE)–TriStar Wellness Solutions, Inc. (OTCBB: TWSI), a health and wellness company that targets opportunities in the self-care and professional marketplace, has acquired HemCon Medical Technologies Inc., a Portland, Oregon-based leading researcher and manufacturer of products for bleeding and wound management. TriStar purchased all the stock of HemCon for $3,075,000 in cash. Effective immediately, HemCon […]

May 13, 2013 |

2013 Board Officers and Directors elected at Oregon Bioscience Association

(Portland, Ore.) — Adrian Polliack, Ph.D., president at SAM Medical, has been appointed chair of the Oregon Bioscience Association (Oregon  Bio) board of directors.  Executive committee members include Ryan Dunlap, treasurer, Galena Biopharma Inc.; and Michael Phillips, secretary and general counsel, Davis Wright Tremaine LLP. Other executive committee members include Abhijit Banerjee, Ph.D., Oregon Health & Science University; Gordon Brown, Yecuris Corp.; Bill Carroll, Meagan Medical/RS Medical;  Juergen Lindner, MSEI/Biotronik USA; and Matt Smits, TE Connectivity.

Along with the officers, serving […]

April 29, 2013 |

Scientific advisers to the C.D.C. have been discussing the details of federal guidance on who qualifies for a Pfizer-BioNTech booster shot and why. A recommendation by the panel is expected… [...]

NIH vouches for new kidney disease diagnostic that doesn't rely on faulty race-based calculations apark Thu, 09/23/2021 - 14:44 [...]

The discussion, which continues on Thursday, could result in most Americans qualifying for an extra shot, or only a select few. [...]

The most common method of assessing the condition may make Black patients seem less ill than they really are, some experts say. A new report calls for scrapping the formula. [...]

A lawsuit brought on by the Montana Medical Association is challenging the state's ban on employer vaccine mandates. The association, along with other hospitals and patient groups, filed a lawsuit Wednesday… [...]